Two private biotechs announced large financing rounds: Mirador Therapeutics raised $250 million in a Series B to expand its precision immunology pipeline and signaled IPO plans, while Orca Bio pulled together $250 million to support the commercial launch of its T‑cell therapy for post-transplant complications. Coverage: Endpoints News and company releases. Mirador will use proceeds to accelerate immunology programs; Orca intends the financing to underwrite manufacturing scale-up, regulatory filings and market entry. Both raises highlight investor willingness to fund later-stage translational plays and near-commercial cell therapies. These rounds may set benchmarks for valuation and syndicate composition for similar cell- and immune-focused companies this year.